The global PD1 non-small cell lung cancer treatment market size is expected to surpass an impressive valuation of US$ 26.96 Billion in 2023 and is projected to reach US$ 61 Billion by 2033, growing at a CAGR of 8.51%
The presence of a strong pipeline for NSCLC is projected to propel growth over the coming years. For instance, fruquintinib (HMPL-013), a drug developed to treat advanced non-small cell lung cancer is in the clinical trial phase. Furthermore, Avelumab developed by Merck KGaA is currently in the pipeline. It is a fully human monoclonal PD-L1 antibody. Thus, the development of such advanced treatments is expected to drive the market during the forecast period.
High growth is attributed to the growing patient population, expected entry of several drugs, and increasing investment by industry players in the Research and Development (R&D) of NSCLC therapy. The increasing prevalence of NSCLC across the globe owing to increasing air pollution and smoking habits amongst people is likely to propel market growth over the coming years.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 26.96 Billion |
| Anticipated Forecast Value (2033) | US$ 61 Billion |
| Projected Growth Rate (2023 to 2033) | CAGR 8.51% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market revenue for PD1 Nonsmall cell lung cancer treatment was US$ 18.2 Billion in 2018 while exhibiting a CAGR of 5.7%. Pharmaceutical companies have begun to develop additional anti-PD-1/PD-L1 antibodies to overcome resistance and are devising further immunotherapy combinations which is creating space for market expansion. More than 20 anti-PD-1/PD-L1 antibodies have been approved or are currently in development. Numerous combination therapies are under development, and several combination therapies have provided positive results in randomized controlled trials which presents growth avenues for the market.
The global increase in cancer cases boosts the global non-small cell lung cancer market during the forecast period. According to American Cancer Society statistics from 2020, the majority of cases of SCLC occur in people between the ages of 60 and 80, with a global death rate of 30,000 per year.
Furthermore, according to WHO data, lung cancer is the second most common cancer in men and women, accounting for around 3 million deaths in 2020. This boosts the market growth. Thus, considering these factors and developments, FMI has estimated the market to gross a value of US$ 61 Billion with a CAGR of 8.51% by end of the forecast period.
New drug approvals to fuel market growth
The rising number of new drug approvals by regulatory authorities for the treatment of non-small cell lung cancer is anticipated to drive the growth of the market. For instance, in May 2019, Pfizer Inc., which is a USA-based multinational pharmaceutical and biotechnology corporation received the European Commission’s (EC) marketing authorization for the LORVIQUA drug, a monotherapy drug used for the treatment of anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). This development will aid in market growth.
Moreover, with the approval of Nivolumab, immune-checkpoint inhibitors (ICIs), mainly anti-programmed cell death-1 (PD-1) antibodies, have rapidly revolutionized cancer treatment which is anticipated to drive the market in the forecast period. The recommendation of combination therapy with an anti-PD-1/PD-L1 antibody and platinum-based chemotherapy as a first-line therapy for patients with advanced NSCLC without driver gene mutations will augment the growth of the PD1 Non-small cell lung cancer treatment market during the forecast period
Rising demand for oral drugs to augment product demand
Oral drugs are expected to boost the market growth. The segment is estimated to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Principal Consultant
Lack of skilled professionals restraining market growth
The dearth of trained professionals who are unaware of treatment methods for this disease may restrict the growth of the global PD1 non-small cell lung cancer treatment market during the forecast period.
High cost of treatment to hamper market expansion
The high cost of drugs is a major blockade for patients to adopt these drugs easily. Thus, presenting challenges for market expansion.
North America rules the market with the highest market share
This region is expected to dominate the market with a market share of 42% during the forecast period. The market in the USA was estimated at US$ 9.2 Billion in 2022. The growth is attributed due to increasing support from the U.S. Government for developing therapies and drugs to treat different types of cancer. The availability of state-of-the-art research facilities and access to advanced testing equipment helps with successful research, which is contributing to market growth.
Furthermore, high research and development activities, the launch of companion diagnostics by industry players, and massive healthcare spending are propelling the growth of the overall regional market to a large extent. ?The cost of treatment which includes chemotherapy, immunotherapy, targeted therapy, radiation, and in some cases, surgery, is vast, and the availability of significant reimbursement in the region is likely to augment market growth.
South Asia to witness the fastest growth in the forecast period
This region is expected to witness the fastest CAGR of 8% in the forecast period. The market in this region is projected to account for 25.5% of revenue by 2033. China is expected to grow at a CAGR of 13.7% with a market valuation to reach US$ 12.2 Billion by end of the forecast period. The growth in this region is attributable to the presence of a large patient population and the rise in research and development activities in the pharmaceutical sector.
Moreover, the presence of companies and growth in the purchasing power of countries like India and China will fuel product demand. Also, the rise in the adoption of therapies for cancer and the adoption of high-tech processing to improve training programs are driving growth in this region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Demand for Targeted Cancer Therapies on the Rise
Targeted therapy is expected to dominate the market by reaching a valuation of US$ 31.7 Billion by end of the forecast period while exhibiting a CAGR of 10%. This segment is expected to continue this trend owing to distinct clinical benefits offered by this therapy such as minimal side effects along with the availability of a number of targeted therapeutics.
In addition, rise in the number of people turning to targeted therapy as a form of treatment for cancer, and targeted therapy is successful in up to 80% of cases. These factors will propel the segment’s growth in the upcoming years.
Hospital Pharmacies account for the Maximum Availability of key Drugs
This segment is expected to account for 52% market share while trailing at a CAGR of 12% during the forecast period. The dominance is due to an increase in the number of hospitalizations of patients suffering from PD1 Non-small cell lung cancer and the presence of skilled professionals within these settings.
The market is fragmented and moderately competitive. The strategies like mergers and acquisitions adopted by major market players will boost the market growth. The major players in the market are Merck Co. & Inc, Bristol-Myers Squibb, F. Hoffmann-La Roche AG, AstraZeneca Plc, Pfizer Inc, Merck KGaA, Novartis AG, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Sanofi, and Agennix AG. Some recent developments in this industry are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 26.96 Billion |
| Market Value in 2033 | US$ 61 Billion |
| Growth Rate | CAGR of 8.51% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The market witnessed a CAGR of 5.7% from 2018 to 2022.
The market is expected to reach US$ 31.7 billion through 2033.
The hospital pharmacies segment is estimated to register a growth rate of 12% until 2033.
North America’s market is expected to dominate with a market share of 42%.
The market is valued at US$ 26.96 billion in 2023.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ million) Analysis By Drug Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Type, 2023 to 2033
5.3.1. Nivolumab
5.3.2. Pembrolizumab
5.3.3. Atezolizumab
5.3.4. Avelumab
5.3.5. Durvalumab
5.4. Y-o-Y Growth Trend Analysis By Drug Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Cancer Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ million) Analysis By Cancer Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Cancer Type, 2023 to 2033
6.3.1. Squamous Cell Carcinoma
6.3.2. Adenocarcinoma
6.3.3. Large-cell Carcinoma
6.4. Y-o-Y Growth Trend Analysis By Cancer Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Cancer Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ million) Analysis By Treatment, 2018 to 2022
7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Treatment, 2023 to 2033
7.3.1. Chemotherapy
7.3.2. Targeted Therapy
7.3.3. Immunotherapy
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2018 to 2022
8.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2023 to 2033
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East and Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. The USA
10.2.1.2. Canada
10.2.2. By Drug Type
10.2.3. By Cancer Type
10.2.4. By Treatment
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Type
10.3.3. By Cancer Type
10.3.4. By Treatment
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Type
11.2.3. By Cancer Type
11.2.4. By Treatment
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Type
11.3.3. By Cancer Type
11.3.4. By Treatment
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. The United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Drug Type
12.2.3. By Cancer Type
12.2.4. By Treatment
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Type
12.3.3. By Cancer Type
12.3.4. By Treatment
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Drug Type
13.2.3. By Cancer Type
13.2.4. By Treatment
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Type
13.3.3. By Cancer Type
13.3.4. By Treatment
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug Type
14.2.3. By Cancer Type
14.2.4. By Treatment
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Type
14.3.3. By Cancer Type
14.3.4. By Treatment
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Drug Type
15.2.3. By Cancer Type
15.2.4. By Treatment
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Type
15.3.3. By Cancer Type
15.3.4. By Treatment
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Drug Type
16.2.3. By Cancer Type
16.2.4. By Treatment
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Type
16.3.3. By Cancer Type
16.3.4. By Treatment
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. The USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Drug Type
17.1.2.2. By Cancer Type
17.1.2.3. By Treatment
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Drug Type
17.2.2.2. By Cancer Type
17.2.2.3. By Treatment
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Drug Type
17.3.2.2. By Cancer Type
17.3.2.3. By Treatment
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Drug Type
17.4.2.2. By Cancer Type
17.4.2.3. By Treatment
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Drug Type
17.5.2.2. By Cancer Type
17.5.2.3. By Treatment
17.5.2.4. By Distribution Channel
17.6. U.K.
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Drug Type
17.6.2.2. By Cancer Type
17.6.2.3. By Treatment
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Drug Type
17.7.2.2. By Cancer Type
17.7.2.3. By Treatment
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Drug Type
17.8.2.2. By Cancer Type
17.8.2.3. By Treatment
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Drug Type
17.9.2.2. By Cancer Type
17.9.2.3. By Treatment
17.9.2.4. By Distribution Channel
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Drug Type
17.10.2.2. By Cancer Type
17.10.2.3. By Treatment
17.10.2.4. By Distribution Channel
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Drug Type
17.11.2.2. By Cancer Type
17.11.2.3. By Treatment
17.11.2.4. By Distribution Channel
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Drug Type
17.12.2.2. By Cancer Type
17.12.2.3. By Treatment
17.12.2.4. By Distribution Channel
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Drug Type
17.13.2.2. By Cancer Type
17.13.2.3. By Treatment
17.13.2.4. By Distribution Channel
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Drug Type
17.14.2.2. By Cancer Type
17.14.2.3. By Treatment
17.14.2.4. By Distribution Channel
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Drug Type
17.15.2.2. By Cancer Type
17.15.2.3. By Treatment
17.15.2.4. By Distribution Channel
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Drug Type
17.16.2.2. By Cancer Type
17.16.2.3. By Treatment
17.16.2.4. By Distribution Channel
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Drug Type
17.17.2.2. By Cancer Type
17.17.2.3. By Treatment
17.17.2.4. By Distribution Channel
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Drug Type
17.18.2.2. By Cancer Type
17.18.2.3. By Treatment
17.18.2.4. By Distribution Channel
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Drug Type
17.19.2.2. By Cancer Type
17.19.2.3. By Treatment
17.19.2.4. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Drug Type
17.20.2.2. By Cancer Type
17.20.2.3. By Treatment
17.20.2.4. By Distribution Channel
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Drug Type
17.21.2.2. By Cancer Type
17.21.2.3. By Treatment
17.21.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Type
18.3.3. By Cancer Type
18.3.4. By Treatment
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Merck Co. & Inc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Bristol-Myers Squibb
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. F. Hoffmann-La Roche AG
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. AstraZeneca Plc.
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Pfizer Inc.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. Merck KGaA
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. Novartis AG
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. GlaxoSmithKline plc.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Takeda Pharmaceutical Company Limited
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Eli Lilly and Company
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Sanofi
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Agennix AG
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
PD1 Non-Small Cell Lung Cancer Treatment Market
